Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

Make your likes visible on Facebook?

Connect your Facebook account to Prezi and let your likes appear on your timeline.
You can change this under Settings & Account at any time.

No, thanks

Alzheimer

No description
by

Otávio Augusto Fernandes

on 26 June 2013

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Alzheimer

Introdução
Biomarcadores para a

Doença de Alzheimer
Otávio Augusto Fernandes Bianco
Patricia Regina Manzine
Orientadora: Marcia Regina Cominetti
Envelhecimento populacional;

Transição epidemiológica;

Grande impacto econômico;
Diagnóstico
Tratamento
Características
Doença de Alzheimer
Síndrome demencial
Neurodegenerativa
Progressiva
Dois marcos
patológicos

Testes cognitivos
Exames de imagem
Análise de Fluídos
Genéticos?
Não existe cura;
Inibidores de acetilcolinesterase;
Tratamento para comportamento;
Tratamentos não farmacológicos.
Depressão
Características
Depressão e DA
Tratamento
Transtorno de Animo
20% da população já teve DP
Diferente de tristeza
Antidepressivos

Psicoterapia
Grande incidência das duas doenças;

Uso de antidepressivos
Biomarcadores
São indicadores de algum processo fisiológico, patológico ou resposta farmacológica
Porque Biomarcadores para DA?
Facilitar o diagnóstico
Prever o progresso da doença
Acompanhar as respostas aos tratamentos
Preço de um Biomarcador
Nature Rev. Drug Discovery 10 (2011) 253-254
O que é?
Proteína transmembrana
α-secretase
Relação com DA
Colciaghi
Bianco
ADAM10
Manzine
ADAM 10 como α- secretase

Reduzido em idosos com DA
Relação do uso de antidepressivos e expressão de ADAM 10.
Considerações finais
Estudo ainda em andamento;
Necessidade de mais sujeitos de pesquisa
Sem relação inicial
Importante para definir as características do biomarcador
Referencias Bibliográficas
1.Roggers, A.B. (2008) Alzheimer's disease: unraveling the mistery. 43.
2.Lopes, M.A. and C.M. Bottino, [Prevalence of dementia in several regions of the world: analysis of epidemiologic studies from 1994 to 2000]. Arq Neuropsiquiatr, 2002. 60(1): p. 61-9.
3.Petersen, R.C., et al., Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2001. 56(9): p. 1133-42.
4.Qin, W., et al., S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One, 2009. 4(1): p. e4183.
5.Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry, 2000. 157(4 Suppl): p. 1-45.
6.Rubio, J.M., et al., Epidemiology of chronic and nonchronic major depressive disorder: results from the national epidemiologic survey on alcohol and related conditions. Depress Anxiety, 2011. 28(8): p. 622-31.
7.White, J.M., ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol, 2003. 15(5): p. 598-606.
8.Buxbaum, J.D., et al., Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci, 1998. 18(23): p. 9629-37.
9.Colciaghi, F., et al., Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology, 2004. 62(3): p. 498-501.
10.Zigman, W., et al., The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference. J Intellect Disabil Res, 1997. 41 ( Pt 1): p. 76-80.
11.Helmer, C., F. Pasquier, and J.F. Dartigues, [Epidemiology of Alzheimer disease and related disorders]. Med Sci (Paris), 2006. 22(3): p. 288-96.
12.Qiu, C.X., B. Winblad, and L. Fratiglioni, [Risk factors for dementia and Alzheimer' s disease-findings from a community-based cohort study in Stockholm, Sweden]. Zhonghua Liu Xing Bing Xue Za Zhi, 2005. 26(11): p. 882-7.
13.Ward, M., Biomarkers for Alzheimer's disease. Expert Rev Mol Diagn, 2007. 7(5): p. 635-46.
14.McKhann, G.M., et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011. 7(3): p. 263-9.
15.Brasil, Conselho Nacional de Saúde. Comitê Nacional de Ética em Pesquisa com Seres Humanos. Resolução 196, 1997.
16.Manzine et al.: ADAM10 as a Biomarker for Alzheimer’s Disease: A Study with Brazilian Elderly.Dement Geriatr Cogn Disord. 2012.
17.Manzine et al.: Correlation Between Mini-Mental State Examination. Journal of Alzheimer's Disease. 2013.
18.Hooper, N.M. and A.J. Turner, The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem, 2002. 9(11): p. 1107-19.
Obrigado!!
otavioafmb@gmail.com
Full transcript